Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Biogen Inc.
  6. News
  7. Summary
    BIIB   US09062X1037

BIOGEN INC.

(BIIB)
  Report
Delayed Nasdaq  -  04:00 2022-09-28 pm EDT
276.61 USD   +39.85%
05:09pUS Stocks Climb Wednesday, Yields Slump After Bank of England Move
MT
04:36pUS Stocks Climb Wednesday Following Bank of England Move
MT
04:29pBiogen's Latest Data for Alzheimer's Drug Raises Likelihood for Approval, May Lead to 'Significant Stock Upside,' RBC Says
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Biogen Says US FDA Accepts NDA, Grants Priority Review for Amyotrophic Lateral Sclerosis Drug

07/26/2022 | 08:59am EDT


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
BIOGEN INC. 39.85% 276.61 Delayed Quote.-17.56%
IONIS PHARMACEUTICALS, INC. 5.09% 44.42 Delayed Quote.38.91%
All news about BIOGEN INC.
05:09pUS Stocks Climb Wednesday, Yields Slump After Bank of England Move
MT
04:36pUS Stocks Climb Wednesday Following Bank of England Move
MT
04:29pBiogen's Latest Data for Alzheimer's Drug Raises Likelihood for Approval, May Lead to '..
MT
04:20pWall Street ends sharply higher as Treasury yields dip
RE
04:16pBiogen, Thor rise; Apple, Equitrans Midstream fall
AQ
04:04pSector Update: Health Care Stocks Finishing Wednesday Trade Near Intra-Day..
MT
04:00pWall Street ends sharply higher as Treasury yields dip
RE
02:56pBiogen shares soar on landmark Alzheimer's data
RE
02:29pWall Street bounces back as Treasury yields dip
RE
01:41pTop Midday Gainers
MT
More news
Analyst Recommendations on BIOGEN INC.
More recommendations
Financials (USD)
Sales 2022 10 006 M - -
Net income 2022 2 340 M - -
Net cash 2022 11,0 M - -
P/E ratio 2022 12,4x
Yield 2022 -
Capitalization 28 702 M 28 702 M -
EV / Sales 2022 2,87x
EV / Sales 2023 2,72x
Nbr of Employees 9 610
Free-Float 85,1%
Chart BIOGEN INC.
Duration : Period :
Biogen Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOGEN INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 32
Last Close Price 197,79 $
Average target price 260,30 $
Spread / Average Target 31,6%
EPS Revisions
Managers and Directors
Michel Vounatsos Chief Executive Officer & Director
Michael R. McDonnell Chief Financial Officer & Executive Vice President
Stelios Papadopoulos Director
Alphonse Galdes EVP-Pharmaceutical Operations & Technology
Mahalakshmi Radhakrishnan Chief Medical Officer & Group Senior VP
Sector and Competitors
1st jan.Capi. (M$)
BIOGEN INC.-17.56%28 702
CSL LIMITED-2.09%88 434
SAMSUNG BIOLOGICS CO.,LTD.-15.06%37 595
WUXI BIOLOGICS (CAYMAN) INC.-47.16%26 568
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.-32.25%19 595
BIOMARIN PHARMACEUTICAL INC.-5.56%15 476